ATE265851T1 - Behandlung von erkrankungen, die vom cytokinwachstumsfaktor verursacht werden - Google Patents

Behandlung von erkrankungen, die vom cytokinwachstumsfaktor verursacht werden

Info

Publication number
ATE265851T1
ATE265851T1 AT96909547T AT96909547T ATE265851T1 AT E265851 T1 ATE265851 T1 AT E265851T1 AT 96909547 T AT96909547 T AT 96909547T AT 96909547 T AT96909547 T AT 96909547T AT E265851 T1 ATE265851 T1 AT E265851T1
Authority
AT
Austria
Prior art keywords
treatment
cytokine growth
pyridone
substituted
growth factor
Prior art date
Application number
AT96909547T
Other languages
English (en)
Inventor
Solomon B Margolin
Original Assignee
Solomon B Margolin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solomon B Margolin filed Critical Solomon B Margolin
Application granted granted Critical
Publication of ATE265851T1 publication Critical patent/ATE265851T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
AT96909547T 1995-03-03 1996-03-04 Behandlung von erkrankungen, die vom cytokinwachstumsfaktor verursacht werden ATE265851T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39796295A 1995-03-03 1995-03-03
PCT/US1996/002737 WO1996027374A1 (en) 1995-03-03 1996-03-04 Treatment of cytokine growth factor caused disorders

Publications (1)

Publication Number Publication Date
ATE265851T1 true ATE265851T1 (de) 2004-05-15

Family

ID=23573420

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96909547T ATE265851T1 (de) 1995-03-03 1996-03-04 Behandlung von erkrankungen, die vom cytokinwachstumsfaktor verursacht werden

Country Status (10)

Country Link
EP (1) EP0813409B1 (de)
JP (1) JPH11501911A (de)
AT (1) ATE265851T1 (de)
AU (1) AU697742B2 (de)
BR (1) BR9607541A (de)
CA (1) CA2214531C (de)
DE (1) DE69632396T2 (de)
ES (1) ES2220975T3 (de)
MX (1) MX9706689A (de)
WO (1) WO1996027374A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716632A (en) * 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US6114353A (en) 1995-03-03 2000-09-05 Margolin; Solomon B. Compositions and method for treatment of lymphomas, leukemias, and leiomyomas
DE69637050T2 (de) * 1995-09-19 2008-06-19 Margolin, Solomon B., Dallas Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer
KR19980020379A (ko) * 1996-09-09 1998-06-25 비. 마르골린 솔로몬 사이토킨 성장인자로 인한 질병의 치료방법
EP1069898B1 (de) * 1998-03-17 2004-05-12 MARGOLIN, Solomon B. Topische antiseptische zusammenstellungen und methoden
DE60029246D1 (de) * 2000-01-24 2006-08-17 Solomon B Margolin Behandlung von brustkarzinomen, astrozytomen, melanomen und verwandten tumoren
WO2001058448A1 (fr) * 2000-02-09 2001-08-16 Shionogi & Co., Ltd. Inhibiteur d'apoptose
JP4614884B2 (ja) * 2003-11-14 2011-01-19 シャンハイ ゲノミックス インク ピリドンの誘導体とその使用
RS53599B1 (sr) * 2005-05-10 2015-02-27 Intermune, Inc. Piridon derivati za modulaciju stresom aktiviranog sistema proteinskih kinaza
RU2491285C2 (ru) * 2006-06-05 2013-08-27 Новартис Аг Органические соединения
JP5627574B2 (ja) 2008-06-03 2014-11-19 インターミューン， インコーポレイテッド 炎症性および線維性疾患を治療するための化合物および方法
CA2824432C (en) * 2011-01-31 2021-10-19 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US8697753B1 (en) 2013-02-07 2014-04-15 Polichem Sa Method of treating onychomycosis
CN106459042B (zh) 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052509A (en) * 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
US4042699A (en) * 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
JPH02215719A (ja) * 1989-02-15 1990-08-28 Yamauchi Akitomo 線維化病変組織の修復並びに線維化病変の阻止剤
US5310562A (en) * 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
JPH08510251A (ja) * 1993-05-07 1996-10-29 ビー マーゴリン、ソロモン 線維症の病変の修復と予防のための組成物および方法

Also Published As

Publication number Publication date
EP0813409A4 (de) 1999-01-07
BR9607541A (pt) 1997-12-23
DE69632396D1 (de) 2004-06-09
MX9706689A (es) 1998-06-30
WO1996027374A1 (en) 1996-09-12
AU697742B2 (en) 1998-10-15
AU5300596A (en) 1996-09-23
EP0813409A1 (de) 1997-12-29
EP0813409B1 (de) 2004-05-06
ES2220975T3 (es) 2004-12-16
CA2214531C (en) 2009-01-20
CA2214531A1 (en) 1996-09-12
DE69632396T2 (de) 2005-05-04
JPH11501911A (ja) 1999-02-16

Similar Documents

Publication Publication Date Title
ATE265851T1 (de) Behandlung von erkrankungen, die vom cytokinwachstumsfaktor verursacht werden
YU47543B (sh) Postupak za dobijanje farmaceutskog preparata za stimulaciju granulocita
RU95109905A (ru) Композиции в жидком, полутвердом, твердом, гелеобразном или пастообразном виде и способ лечения заболеваний полости рта
DE69634609D1 (de) Analgesiche synergie durch gleichzeitige verabreichung von subanalgesichen doseneines mu-opioidanagonisten und eines kappa - 2- opioidanagonisten
ATE252899T1 (de) Schilddrüsenhormone enthaltende mittel
RU95107663A (ru) Бензо-конденсированные лактамы, ускоряющие высвобождение соматотропного гормона, способы их получения, способы лечения, композиции
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
MD990262A (en) Method of prophylaxis or delay of the Alzheimer disease start and therapeutic product effective for prevention of said disease
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
SE9703191D0 (sv) Medicament for improvement of duration of muscle function or treatment of muscle disorders or diseases
DE69602412D1 (de) Ophthalmische Zubereitung zur Behandlung oder Prävention von trockenem Auge und Krankheiten, die dadurch verursacht werden, enthaltend 12-Sulfodehydroabietsäure
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
MX9602973A (es) Uso de un antagonista de bradiquinina en una composicion, cosmetica, farmaceutica o dermatologica y la composicion obtenida.
UA35567C2 (uk) Фармацевтичний препарат для лікування хворих з порушеннями функції коагуляції, спосіб лікування таких хворих, спосіб одержання фармацевтичного препарату
DK164441C (da) Anvendelse af et piperidinderivat til fremstilling af et farmaceutisk praeparat til behandling af smertetilstande
UA35611C2 (uk) Композиція місцевого застосування для інгібування росту волос у ссавців, спосіб із її використанням та композиція місцевого застосування для доставки водорозчинного фармакологічного засобу до шкіри
ATE133859T1 (de) Pharmazeutische zubereitungen mit verzögerter freisetzung zur behandlung periodontaler erkrankungen
ATE282406T1 (de) Arzneimittel und verfahren zur behandlung von intrazellulären infektionen
ATE135909T1 (de) Verfahren zur behandlung von akne
ATE409028T1 (de) Arzneien zur behandlung von nervenerkrankungen
ATE157871T1 (de) Arzneimittel zur therapeutischen und prophylaktischen behandlung von krankheiten, die durch hyperplasie der glatten muskelzellen bedingt sind
ATE316379T1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
BG105275A (en) Tan-1057 derivatives
HUP9902415A2 (hu) Azonnal felszabaduló szilárd beadási formák és eljárás azok előállítására
CA2429793A1 (en) Interferon therapeutic effect enhancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties